Adefovir Dipivoxil

Patients should be monitored closely for adverse events when Adefovir dipivoxil is co-administered with drugs that are excreted renally or with other drugs known to affect renal function. Hepatic function should be monitored at repeated intervals with both clinical and laboratory follow-up for at least several months in patients who discontinue Adefovir dipivoxil. It is important to monitor renal function for all patients during treatment. Caution should be exercised when prescribing Adefovir dipivoxil to adolescents with underlying renal dysfunction, and renal function in these patients should be closely monitored. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease. Obtaining HIV antibody testing prior to starting Adefovir dipivoxil is important.